Definium Therapeutics, Inc. (DFTX): debt financing — MindMed amends credit facility, gets $42M new term loan; total capacity up to $120M

Definium Therapeutics, Inc.

Restated credit facility provides up to $120M in term loans; $42M funded immediately to refinance existing debt.
Interest rate lowered to greater of 10.25% or Prime+2.75%; maturity extended to April 1, 2029.
Lenders may convert up to $7M of debt into common shares at $4.01-$9.00 per share.
Additional $28M tranche available upon clinical/regulatory milestones; $50M discretionary tranche.
Minimum liquidity covenant effective July 1, 2026 if milestones missed; waived if market cap >$500M.

Key facts

Extracted from this filing and checked against the source text.

Debt Financings SEC 8-K Item 2.03/2.04 confidence 0.9

Definium Therapeutics, Inc. amended credit facility of up to $120.0 million with K2 HealthVentures LLC at the greater of (x) 10.25% and (y) the sum of (a) the Prime Rate as reported in T maturing April 1, 2029.

Instrument: credit facility
Principal: up to $120.0 million
Counterparty: K2 HealthVentures LLC
Rate: the greater of (x) 10.25% and (y) the sum of (a) the Prime Rate as reported in T
Maturity: April 1, 2029
Event: amendment

Exact text from the filing

Agreement”). The First Amendment and the Amended Credit Agreement provide for, among other things: (i) an aggregate principal amount of term loans (the “Term Loans”) of up to $120.0 million, consisting of (A) a new Restatement First Tranche Term Loan (as defined in the Amended Credit Agreement) of $42.0 million, which was funded on the Effective Date, a portion of

View on SEC.gov

222 debt financings filed in the last 30 days. Browse all debt financings →

Definium Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-25-036841

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.